Skip to main content
Explore URMC

menu

Breast cancer: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Research Question:
What are the effects (good or bad) of adding a chemotherapy drug called carboplatin to the usual chemotherapy drugs given after surgery?

Basic Study Information

Purpose:
This study has two study groups. Group 1 will get the usual chemotherapy drugs used for this type of cancer: doxorubicin and cyclophosphamide, followed by paclitaxel. Group 2 will get the usual chemotherapy drugs used for this type of cancer: doxorubicin and cyclophosphamide, followed by paclitaxel plus the chemotherapy drug called carboplatin.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02488967?term=Br003&rank=2
Study Reference #: CBRS-16091

Lead Researcher (Principal Investigator)

Lead Researcher: Allison Magnuson

Study Contact Information

Study Coordinator: Kate Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Return to Search